Lonza to expand inhalation capabilities at Tampa site
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
The facility is among 12 centres established worldwide, and the first in Asia
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
The new facility is scheduled to start operation in the first half of 2024
The plant is scheduled to come on stream in September 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Subscribe To Our Newsletter & Stay Updated